

17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



PRESS RELEASE

Sun Pharma's lead molecule enters Phase II in the US

Mumbai, October 20: Sun Pharma, the speciality pharma company, today announced that its lead anti-allergic molecule has received permission from the USFDA to enter Phase II trials in the US. This Phase II trial is being conducted in the US directly by the company, using a reputed CRO. This is, so far, the first IND filing and phase II study in the US for an Indian company working independently without a partner.

Based on pre-clinical and Phase I studies, the product appears to have a safer pharmacologic profile, with faster onset of action without major side effects.

Dilip Shanghvi, the Chairman and Managing Director of Sun Pharma, said, " We are excited about this NCE candidate, our first-ever lead in Phase II. In our estimate, the Phase II trials should be completed on our own strength, technical as well as financial."

Sun Pharma conducts drug discovery research in facilities at Baroda and Mumbai, India. This is the first lead molecule in human trials from the company's innovative research program. The company has shared plans to demerge its innovative R&D programs into a new company by this fiscal, and expects to share more information about the innovative pipeline a month prior to listing the new company.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. The company is pursuing NCE and NDDS programs with the aim to bring products based on proprietary technology to market. More information about the company can be found at www.sunpharma.com.

Contact

Uday Baldota
Tel : +91 22 6645 5645, Ext 225
Tel Direct : +91 22 66455525
Mobile : +91 98670 10529
E mail: uday.baldota@sunpharma.com

Mira Desai
Tel : +91 22 6645 5645, Ext 184
Tel Direct : +91 22 66455584
Mobile : +91 98219 23797
E mail : miradesai@sunpharma.com